Cancer Research UK
- Country
- 🇬🇧United Kingdom
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 1K
- Market Cap
- -
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
- Conditions
- Solid TumourHaematological MalignancyMalignant NeoplasmNeoplasms by Histologic TypeNeoplasms by SiteCancerMalignancyGliomaNeuroblastomaGastric Cancer
- Interventions
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT06988475
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧University Hospital Birmingham, Birmingham, United Kingdom
🇬🇧Bristol Haematology and Oncology Centre, Bristol, United Kingdom
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
- Conditions
- Advanced Solid TumoursSquamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell LungColorectal NeoplasmsTriple Negative Breast NeoplasmsCarcinoma, Renal Cell (Clear Cell Only)Esophageal NeoplasmsStomach Neoplasms (Excluding Gastrointestinal Stromal Tumors)Uterine Cervical NeoplasmsOvarian Neoplasms
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 167
- Registration Number
- NCT06380816
- Locations
- 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
- Conditions
- Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, FollicularLymphoma, B-CellLarge B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 84
- Registration Number
- NCT06045910
- Locations
- 🇬🇧
University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧Cambridge University Hospitals, Cambridge, United Kingdom
🇬🇧St James's University Hospital, Leeds, United Kingdom
HTL0039732 in Participants With Advanced Solid Tumours
- Conditions
- PheochromocytomasUterine Cervical NeoplasmsKidney NeoplasmsProstatic Neoplasms, Castration-ResistantStomach NeoplasmsLung NeoplasmsMesothelioma, MalignantNeoplasmsEsophageal NeoplasmsHead and Neck Neoplasms
- Interventions
- Drug: HTL0039732 CapsulesDrug: HTL0039732 Capsules and atezolizumab infusion
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 150
- Registration Number
- NCT05944237
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧Velindre Cancer Centre, Cardiff, United Kingdom
🇬🇧Clatterbridge Cancer Centre, Liverpool, United Kingdom
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
- Conditions
- Haematological MalignancyColorectal NeoplasmsUrinary Bladder NeoplasmGallbladder NeoplasmsSalivary Gland NeoplasmLung NeoplasmPancreatic NeoplasmOvarian NeoplasmsProstatic NeoplasmSkin Neoplasm
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT05786716
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧University Hospital Birmingham, Birmingham, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, United Kingdom
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
- Conditions
- Haematological MalignancyMalignant NeoplasmLymphoproliferative DisordersNeoplasms by Histologic TypeNeoplasms by SiteCancerAnaplastic Large Cell LymphomaLymphomaRenal Cell CarcinomaNeuroblastoma
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT05770037
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧University Hospital Birmingham, Birmingham, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, United Kingdom
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-positive Cancers.
- Conditions
- Haematological MalignancyLymphoproliferative DisordersMalignancyMalignant NeoplasmNeoplasms by Histologic TypeNeoplasms by SiteCancerBrain NeoplasmsMelanomaGlioma
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT05770544
- Locations
- 🇬🇧
Cardiff Children's Hospital, Cardiff, United Kingdom
🇬🇧Sheffield's Children's Hospital, Sheffield, United Kingdom
🇬🇧Belfast City Hospital, Belfast, United Kingdom
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
- Conditions
- MalignancyMalignant NeoplasmLymphoproliferative DisordersNeoplasms by Histologic TypeNeoplasms by SiteCancerColorectal NeoplasmsEndometrial NeoplasmsMelanomaSolid Tumours
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT05770102
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧University Hospital Birmingham, Birmingham, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, United Kingdom
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
- Conditions
- Haematological MalignancyMelanomaThyroid Cancer, PapillaryOvarian NeoplasmsColorectal NeoplasmsLaryngeal NeoplasmsCarcinoma, Non-Small-Cell LungGliomaMultiple MyelomaErdheim-Chester Disease
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT05768178
- Locations
- 🇬🇧
University Hospital Birmingham, Birmingham, United Kingdom
🇬🇧Bristol Haematology and Oncology Centre, Bristol, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, United Kingdom
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
- Conditions
- Haematological MalignancySolid Tumour
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 825
- Registration Number
- NCT05722886
- Locations
- 🇬🇧
Cardiff Children's Hospital, Cardiff, United Kingdom
🇬🇧Sheffield's Children's Hospital, Sheffield, United Kingdom
🇬🇧Belfast City Hospital, Belfast, United Kingdom